Through co-immunoprecipitation, we observed an interaction between PARP1 and TOPBP1 in pancreatic cancer cell lines, indicating the involvement of complex molecular regulatory mechanisms in the combined effects of olaparib with shTOPBP1 or ATRi. This evidence concerns the gene PARP1 and pancreatic neoplasm.